E Van Cutsem1, Y-J Bang2, W Mansoor3, R D Petty4, Y Chao5, D Cunningham6, D R Ferry7, N R Smith8, P Frewer9, J Ratnayake8, P K Stockman8, E Kilgour8, D Landers8. 1. Unit of Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium. 2. Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Korea. 3. The Christie NHS Foundation Trust, Manchester. 4. Medical Research Institute, University of Dundee, Dundee. 5. Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. 6. Gastrointestinal and Lymphoma Unit, Royal Marsden Hospital NHS Foundation Trust, Surrey. 7. Clinical Oncology, New Cross Hospital, Wolverhampton. 8. Oncology Innovative Medicines and Early Development, AstraZeneca, Macclesfield. 9. Oncology Innovative Medicines and Early Development, AstraZeneca, Cambridge, UK.
Abstract
BACKGROUND: Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine kinase inhibitor with potent preclinical activity in FGFR2 amplified gastric adenocarcinoma SNU16 and SGC083 xenograft models. The randomized phase II SHINE study (NCT01457846) investigated whether AZD4547 improves clinical outcome versus paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma displaying FGFR2 polysomy or gene amplification detected by fluorescence in situ hybridization. PATIENTS AND METHODS: Patients were randomized 3:2 (FGFR2 gene amplification) or 1:1 (FGFR2 polysomy) to AZD4547 or paclitaxel. Patients received AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off schedule of a 21-day cycle or intravenous paclitaxel 80 mg/m2 administered weekly on days 1, 8, and 15 of a 28-day cycle. The primary end point was progression-free survival (PFS). Safety outcomes were assessed and an exploratory biomarker analysis was undertaken. RESULTS: Of 71 patients randomized (AZD4547 n = 41, paclitaxel n = 30), 67 received study treatment (AZD4547 n = 40, paclitaxel n = 27). Among all randomized patients, median PFS was 1.8 months with AZD4547 and 3.5 months with paclitaxel (one-sided P = 0.9581); median follow-up duration for PFS was 1.77 and 2.12 months, respectively. The incidence of adverse events was similar in both treatment arms. Exploratory biomarker analyses revealed marked intratumor heterogeneity of FGFR2 amplification and poor concordance between amplification/polysomy and FGFR2 mRNA expression. CONCLUSIONS: AZD4547 did not significantly improve PFS versus paclitaxel in gastric cancer FGFR2 amplification/polysomy patients. Considerable intratumor heterogeneity for FGFR2 gene amplification and poor concordance between FGFR2 amplification/polysomy and FGFR2 expression indicates the need for alternative predictive biomarker testing. AZD4547 was generally well tolerated.
BACKGROUND: Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine kinase inhibitor with potent preclinical activity in FGFR2 amplified gastric adenocarcinoma SNU16 and SGC083 xenograft models. The randomized phase II SHINE study (NCT01457846) investigated whether AZD4547 improves clinical outcome versus paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma displaying FGFR2 polysomy or gene amplification detected by fluorescence in situ hybridization. PATIENTS AND METHODS: Patients were randomized 3:2 (FGFR2 gene amplification) or 1:1 (FGFR2 polysomy) to AZD4547 or paclitaxel. Patients received AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off schedule of a 21-day cycle or intravenous paclitaxel 80 mg/m2 administered weekly on days 1, 8, and 15 of a 28-day cycle. The primary end point was progression-free survival (PFS). Safety outcomes were assessed and an exploratory biomarker analysis was undertaken. RESULTS: Of 71 patients randomized (AZD4547 n = 41, paclitaxel n = 30), 67 received study treatment (AZD4547 n = 40, paclitaxel n = 27). Among all randomized patients, median PFS was 1.8 months with AZD4547 and 3.5 months with paclitaxel (one-sided P = 0.9581); median follow-up duration for PFS was 1.77 and 2.12 months, respectively. The incidence of adverse events was similar in both treatment arms. Exploratory biomarker analyses revealed marked intratumor heterogeneity of FGFR2 amplification and poor concordance between amplification/polysomy and FGFR2 mRNA expression. CONCLUSIONS: AZD4547 did not significantly improve PFS versus paclitaxel in gastric cancer FGFR2 amplification/polysomy patients. Considerable intratumor heterogeneity for FGFR2 gene amplification and poor concordance between FGFR2 amplification/polysomy and FGFR2 expression indicates the need for alternative predictive biomarker testing. AZD4547 was generally well tolerated.
Authors: Seung Tae Kim; In Kyoung Lee; Eran Rom; Roy Sirkis; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Kyoung-Mee Kim; Avner Yayon; Jeeyun Lee Journal: Am J Transl Res Date: 2019-07-15 Impact factor: 4.060
Authors: Elizabeth Won; Azfar Basunia; Walid K Chatila; Jaclyn F Hechtman; Joanne F Chou; Geoffrey Y Ku; Sree B Chalasani; Michelle S Boyar; Zoe Goldberg; Avni M Desai; Yaelle Tuvy; Michael F Berger; Laura Tang; David P Kelsen; Mark Schattner; David H Ilson; Marinela Capanu; David B Solit; Nikolaus Schultz; Yelena Y Janjigian Journal: Clin Cancer Res Date: 2019-04-05 Impact factor: 12.531
Authors: Michael M Fisher; Gopika SenthilKumar; Rong Hu; Steve Goldstein; Irene M Ong; Margot C Miller; Sean R Brennan; Saakshi Kaushik; Lindsey Abel; Kwangok P Nickel; Gopal Iyer; Paul M Harari; Randall J Kimple; Andrew M Baschnagel Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-13 Impact factor: 7.038
Authors: Shumei Kato; Ryosuke Okamura; Scott M Lippman; Razelle Kurzrock; Joel M Baumgartner; Hitendra Patel; Lawrence Leichman; Kaitlyn Kelly; Jason K Sicklick; Paul T Fanta Journal: Clin Cancer Res Date: 2018-10-22 Impact factor: 12.531
Authors: Francesco Facchinetti; Antoine Hollebecque; Rastislav Bahleda; Yohann Loriot; Ken A Olaussen; Christophe Massard; Luc Friboulet Journal: Clin Cancer Res Date: 2019-10-04 Impact factor: 12.531